# ClinicalTrials.gov record NCT04525157

> PeptideScanner retained ClinicalTrials.gov record NCT04525157 at 2026-07-30T19:08:50.172Z. Its registry update date was 2023-09-22, and PeptideScanner's reviewed identity mapping was afamelanotide.

- Evidence object: `story:clinicaltrials-gov-nct04525157-afamelanotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-09-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04525157-afamelanotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04525157-afamelanotide-v1.json
- Content SHA-256: `7cc9092b34786f96e8d26e861a67174a9b4bc7f3dbd987f279e709f3f37e886e`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT04525157 ([`ctg-observation-nct04525157-2023-09-22-afb0b3a48d89`](#source-ctg-observation-nct04525157-2023-09-22-afb0b3a48d89))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04525157 at 2026-07-30T19:08:50.172Z. Its registry update date was 2023-09-22, and PeptideScanner's reviewed identity mapping was afamelanotide. ([`ctg-observation-nct04525157-2023-09-22-afb0b3a48d89`](#source-ctg-observation-nct04525157-2023-09-22-afb0b3a48d89))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04525157 at 2026-07-30T19:08:50.172Z. Its registry update date was 2023-09-22, and PeptideScanner's reviewed identity mapping was afamelanotide. ([`ctg-observation-nct04525157-2023-09-22-afb0b3a48d89`](#source-ctg-observation-nct04525157-2023-09-22-afb0b3a48d89))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04525157-2023-09-22-afb0b3a48d89`](#source-ctg-observation-nct04525157-2023-09-22-afb0b3a48d89))

## Sources

<a id="source-ctg-observation-nct04525157-2023-09-22-afb0b3a48d89"></a>
- **ClinicalTrials.gov record NCT04525157 · retained source version 2023-09-22:afb0b3a48d8969e44efa3905f333ac1bd1c8ab4dc26e9fc87b0c183693b417b2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04525157) (`ctg-observation-nct04525157-2023-09-22-afb0b3a48d89`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04525157." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04525157-afamelanotide-v1.json SHA-256: 7cc9092b34786f96e8d26e861a67174a9b4bc7f3dbd987f279e709f3f37e886e.